A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension

Blood Pressure

Volumn 18, Issue 3, 2009, Pages 149-156

  Karlson, Bjrn Wilgot ^a   Zetterstrand, Sofia ^a   Olofsson, Bertil ^a   Elmfeldt, Dag ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Blood pressure; Candesartan; Combination therapy; Doseresponse; Hydrochlorothiazide; Hypertension

Indexed keywords

CANDESARTAN; HYDROCHLOROTHIAZIDE; PLACEBO;

ARTICLE; CLINICAL TRIAL; DATA BASE; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; REDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; CLINICAL PROTOCOLS; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; PATIENTS; PLACEBOS; RESEARCH; SYSTOLE; TETRAZOLES;

EID: 70849130388     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050902975155     Document Type: Article

References (21)

1. Guidelines Subcommittee. 1 999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999;17:151-183.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R. Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187. (Pubitemid 46924065)
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
4. Easthope SE, Jarvis B. Candesartan cilexetil -An update of its use in essential hypertension. Drugs. 2002;62:1253-1287.
5. Lacourcière Y, Asmar R. A comparison of the effi cacy and Du ration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients -A placebo-controlled, forced titration study. Am J Hypertens. 1999;12:1181-1187.
6. Elmfeldt D, Olofsson B, M eredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press. 2002;11:293-301.
7. Ramsay LE, Yeo WW, C hadwick IG, J ackson PR. Diuretics. In: JD Swales, editor. Textbook of hypertension. Blackwell Scientifi c: Oxford; 1994.
8. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med. 1996;101(Suppl. 3A): 71S-82S.
9. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiaziDe combination -A review of its use in hypertension. Drugs. 2002;62:787-816.
10. Edes I ; for the Multicentre Study Group. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiaziDe 25 mg provides the full additive antihypertensive effect of the components. Clin Drug Invest. 2009;29(5):293-304.
11. Papademetriou V, Reif M, Henry D, N eutel JM, L evine JH, Hardison JD, et al. Combination therapy with candesartan cilexetil and hydrochlorothiaziDe in patients with systemic hypertension. J Clin Hypertens. 2000;2:372-378.
12. Mimran A, Cifková S, Wiecek A. Antihypertensive effect and tolerability of a low-dose combination ofcandesartan cilexetil and hydrochlorothiazide. J Hypertens. 1998;16(Suppl. 2) :S244.
13. Philipp T, L etzel H, A rens H-J. D ose-fi nding study of candesartan cilexetil plus hydrochlorothiaziDe in patients with mild to moderate hypertension. J Hum Hypertens. 1997;11(Suppl. 2): S67-S68.
14. McGill JB, R eilly PA. T elmisartan plus hydrochlorothiaziDe versus telmisartan or hydrochlorothiaziDe monotherapy in patient with mild to moderate hypertensin; A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther. 2001;23:833-850.
15. Pool JL, G lazer R, W einberger M, A lvarado R, J ie H, G raff A. Comparison of valsartan/hydrochlorothiaziDe combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive aDults. Clin Ther. 2007;29:61-73.
16. Flack JM. M aximising antihypertensive effects of angiotensin II receptor blockers with thiaziDe diuretic combination therapy: focus on irbesartan/hydrochlorothiazide. Int J Clin Pract. 2007;61:2093-2102.
17. Burgess E, M uirhead N, De Cotret P R, C hiu A, P ichette V, Tobe S, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol. 2009. DOI: 10.1681/ ASN.2008040416.
18. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
19. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events in indiviDu als with and without diabetes mellitus. Results of prospectively- designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.
20. Zanchetti A, E lmfeldt D. Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) -A review. Blood Press. 2006;15:71-79.
21. Hansson L, Zanchetti A, C arruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762. (Pubitemid 28269185)